Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Maruho Aspires to Get Back on Growth Track on New Drug Launches: President
April 12, 2021
- Kobayashi Kako’s Seima Factory Operations Still Halted Even after 60-Day Order Lifted
April 12, 2021
- Daiichi Sankyo Kicks Off Japan PII for Pexidartinib for TGCT
April 12, 2021
- Drug Reps Increase Online Meetings in February amid Emergency: Intage
April 9, 2021
- Hisamitsu’s Sales Sag 18.8% on Price Cuts, Gx, COVID-19
April 9, 2021
- Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
- Daiichi Sankyo Kicks Off PI/II Study for Menin Inhibitor in AML/ALL
April 9, 2021
- Teijin Pharma Set to Transform Biz, Weather Feburic Patent Cliff with Takeda’s DPP-4s
April 8, 2021
- Astellas Ended Scholarship Donation to Clear Up Doubts on Inducing Prescriptions, No Major Issues Seen after 1 Year
April 8, 2021
- Japan Ethical Drug Sales Fall 2.8% in FY2020: Encise
April 8, 2021
- HUYA Files HBI-8000 for PTCL in Japan: Meiji
April 8, 2021
- Japan Ethical Drug Sales Down 3.8% in February: Crecon
April 8, 2021
- Shonan iPark Partners with UK Bioscience Hub
April 7, 2021
- Takeda Sees FY2021 as Inflection Year for Pipeline, 4 Potential Approvals from 6 Submission-Planned Assets
April 7, 2021
- AstraZeneca's COVID-19 Vaccine as Effective for UK Variant:Exec
April 7, 2021
- AstraZeneca Looks to Become Top Drug Maker in Japan by 2025
April 7, 2021
- Daiichi Sankyo Looks to Rack Up Sales of 1.6 Trillion Yen in FY2025, 3 ADCs as Drivers
April 6, 2021
- Astellas, Toa Eiyo to End Sales Collaboration in March 2022
April 6, 2021
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…